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Microsphere based drug delivery systems show great advantages for tissue engineering. However, it is still
a big challenge to fabricate microspheres with capability in delivering and controlled releasing multiple
growth factors. In the present study, double-layered microspheres consisting of an inner-layer of small
core particles and an outer-layer of big shell particles were developed to sequentially release cell
homing factors (SDF-1) and osteoinductive growth factors (BMP-2) for bone regeneration. In vitro
release testing showed that bioactivity of both growth factors retained within the microspheres and
differential release of SDF-1 and BMP-2 was achieved. Microspheres with both growth factors showed
an obvious chemotaxis effect on preosteoblasts by inducing more cell migration. In osteoinductive
ability tests, the microspheres with both growth factors showed higher ALP activity and more
mineralized modules than control groups after culturing for 2 weeks. The expression of bone
development transcription factors (Runx2, OCN, Osterix) as well as Smad signals (Smad 1, 5, 8) showed
higher gene expression in the dual growth factor group. Our results suggest that a double-layered
microsphere system enhances the recruitment of osteogenic cells and osteoinduction, which provides
a promising platform for bone regeneration.1. Introduction
Microsphere based drug delivery systems receive great interest
for various biomedical applications where therapeutic agents
can be released in a controllable manner.1 Polymeric micro-
spheres are ideal vehicles for many controlled delivery appli-
cations due to their good biocompatibility, high bioactivity and
sustained drug release characteristics.2–4 Compared to other
drug delivery systems, microspheres offer advantages including
the ability to encapsulate and protect therapeutic molecules
with large sizes such as growth factors as well as easy admin-
istration through needles etc.5–7 Various techniques such as
spray-drying,8 emulsion,9 phase separation10 and electrospray11
have been developed to prepare microspheres. Conventional
solid microspheres usually release the loaded drugs usingeensland, Brisbane, Queensland, 4006,
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hemistry 2018a single release behavior due to their simple structure. For
biomedical applications, there is an increased requirement for
the development of multi-drug delivery methods which can
release the drugs in a controlled and sequential way. For example
for bone tissue engineering it is demonstrated that controlled
release of different biochemical cues (e.g. growth factors) in
a designed manner recruits more host circulating stem cells and
fastens the bone regeneration process, which may provide
systematic therapeutic effects compared to a single cue.12–15
One important application of microsphere based delivery
systems is for the treatment of large bone defects caused by
infections, injuries or congenital deformity, which remains
a clinical challenge. Bone is a highly dynamic tissue that
involves continuous remodeling accompanied by osteoclastic
bone resorption and osteoblastic bone formation. Under phys-
iological conditions, bone repair can be performed by attracting
mesenchymal stem cells (MSCs) to the defect sites and further
directing their differentiation towards osteoblasts under
a precise regulation of various growth factors at different time
points. For example, stromal cell derived factor-1 (SDF-1),
a member of the CXC chemokine family, induces the migra-
tion of progenitor/stem cells to the bone defect area during the
acute phase and initiates the regeneration process.12,16 Bone
morphogenetic protein-2 (BMP-2), is an important osteoinduc-
tive growth factor, has been approved by the US Food and Drug
Administration (FDA) for clinical use for the induction of boneRSC Adv., 2018, 8, 16503–16512 | 16503
RSC Advances Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
4 
M
ay
 2
01
8.
 D
ow
nl
oa
de
d 
on
 5
/3
1/
20
19
 5
:5
1:
29
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineformation via the stimulation of osteogenic differentiation of
MSC.17 More importantly, it has been reported that SDF-1
signaling contributes to the osteogenic differentiation of
mesenchymal cells induced by bone morphogenetic protein-2
(BMP-2).12 A delivery system that sequentially releases
designed growth factors, for example rst to release chemokine
which triggers the migration of stem cells and progenitor cells
to injury sites and secondly to release osteoinductive growth
factors which are necessary for the following osteogenic differ-
entiation, may be of great benet for the treatment of bone
defects, which is difficult to achieve by conventional micro-
spheres with simple structure.
To address such challenges, microspheres with core–shell
structure have been developed to load multi-drugs and to tail
the release prole. For example, a double-emulsion approach
has been used to prepare microcapsules using immiscible
solutions.7 However, important limitations exist with these
approaches such as uncontrolled architecture of the synthe-
sized microcapsules, and the use of organic solvents in the
synthetic process denaturing the fragile biochemical cues e.g.
growth factors. It is still a challenge to fabricate a microsphere
based delivery system that is able to sequentially release growth
factors while maintaining their bioactivities and functionalities.
Electrospray provides a simple and robust technique for
fabricating microsphere with different sizes from a broad range
of biocompatible polymers.11 Alginate, has been widely used in
pharmaceutical applications due to its excellent biocompati-
bility, minimal binding interactions with tissue cells and can be
ionically crosslinked into hydrogels by divalent cations, e.g.
calcium.18 Alginate degrades slowly due to dissociation of the
ionic crosslinks, where drug release is achieved. The drug
release rate can be also controlled via modication of alginate
with other polymers such as chitosan.19 Alginate microspheres
can be easily obtained with electrospray method.20 With a two-
step electrospray process, alginate microspheres with double-
layered structure can be obtained with small core micro-
spheres and large shell microspheres. Such architectures can
encapsulate different types of drugs and control the release
kinetics which are suitable for growth factors delivery for bone
repair and may provide extra benets.
In this study, a novel drug-delivery system based on double-
layered microspheres was fabricated, which differentially
released SDF-1 and BMP-2. The initially released SDF-1 facili-
tates the recruitment of MSCs to the injury sites, subsequently
followed by the release of BMP-2 inducing the osteogenic
differentiation of MSCs. The drug release proles were tested in
vitro. The homing effect of stem cells/progenitors into the
microspheres through a chemotaxis assay with a trans-wells
system. The osteoinductive ability of the synthesized MDS
with SDF-1/BMP-2 were tested on bone marrow stromal stem
cells (BMSCs).
2. Materials and methods
2.1. Materials
Alginic acid sodium salt (AS, from brown algae, bioreagent),
chitosan (molecular weight 50–190 kDa, 75–85% deacetylated),16504 | RSC Adv., 2018, 8, 16503–16512albumin-uorescein isothiocyanate conjugate (FITC–albumin,
$7 mol FITC per mol albumin), albumin-
tetramethylrhodamine isothiocyanate bovine (TRITC–
albumin, $0.5 mol TRITC per mol albumin), calcium chloride
(anhydrous, bioreagent), Tween 80 (premium) and acetic acid
($99.7%) were purchased from Sigma-Aldrich Corp. Stromal-
cell derived factor-1 (SDF-1) and bone morphogenetic protein-
2 (BMP-2) were purchased from GenScript, United States. All
chemicals were used as received without further purication.2.2. Preparation of alginate double-layered microsphere
Double-layered microspheres were prepared via a two steps
electrospray method. A stem cell homing inducer (SDF-1) was
loaded into the shell layer and a bone tissue regeneration
inducer (BMP-2) was loaded into the core layer. In the rst step,
BMP-2 solution (containing 0.1% Tween 80, 1.5% AS and 6.67
mg mL1 BMP-2) was introduced into a home-made electrospray
device.20 The solution was loaded in a syringe that was
controlled by an electrical pump ejecting the core layer via
a blunt stainless steel needle, which served as a charged spin-
neret. A grounding dish lled with 4% CaCl2 aqueous solution
was placed underneath the needle at a distance of 10 cm. A high
voltage (30 kV) was applied between the needle and grounding
dish by a power supply (TianJin Dongwen High Voltage Power
Supply Co., Ltd, China). Under this high voltage, AS/BMP-2
microdroplets were jetted toward the CaCl2 solution and
microspheres were formed. Those AS/BMP-2 microspheres were
collected by centrifugation (1000 rpm, 5 min) and washed with
distilled water. Then the microspheres were coated with a layer
of chitosan by stirring in 0.1% chitosan/acetic acid solution
(1%, pH was adjusted to 5.5) for 30 minutes. The products were
washed with acetic acid once and distilled water twice.
In the second step, those AS/BMP-2 microspheres coated
with chitosan were mixed with AS/SDF-1 solution containing
0.1% Tween 80, 1.5% AS and 3.34 mg mL1 SDF-1 by gentle
stirring. Then the mixture was introduced to the electrospray
device and went through a second electrospray process with
a voltage of 30 kV. The products were washed with distilled
water three times and freeze-dried for storage. Those micro-
spheres containing both SDF-1 and BMP-2 were denoted as S-B
group. For comparison, microspheres with BMP-2 only (in the
core layer, B group), SDF-1 only (in the shell layer, S group) or
without any growth factor (O group) were also fabricated.
For the fabrication of alginate microspheres with 3 chitosan
layers, rst alginate microspheres were prepared using above
method. Then those microspheres were dispersed in 0.1%
chitosan/acetic acid solution (1%, pH was adjusted to 5.5) for 30
minutes. Aer washing with water, the obtained microspheres
were stirred in 0.1% alginate solution for 30 min. This process
repeated for three times until the microspheres were coated
with three layers of chitosan (chitosan–alginate–chitosan–algi-
nate–chitosan). Aer that those microspheres went through
another electrospun process to form the double-layered struc-
ture. For lysozyme loaded microspheres 4 mg mL1 lysozyme
water solution was added to the alginate (1.5%) and Tween 80
(0.1%) solution to fabricate the inner microsphere.This journal is © The Royal Society of Chemistry 2018
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View Article OnlineIn order to conrm the location of loaded growth factors
inside the microspheres, FITC–albumin and TRITC–albumin
were used as model proteins and loaded into this double-
layered microsphere using the same procedure. The samples
were observed under a uorescence microscope (LEICA DMi8,
Leica Microsystems, Germany).
2.3. Characterization of the microspheres
The morphology of the double-layered microspheres was
observed with an optical microscope (LEICA DMi8, Leica
Microsystems, Germany) and scanning electron microscopy
(Phenom G2 Pro, Netherland). For optical microscopy observa-
tion, the microparticles were dispersed in phosphate buffered
saline (PBS) and placed on a glass slide. Zeta potential
measurements were carried out at 25 C using a Zetasizer Nano-
ZS from Malvern instruments. The samples were dispersed at
10 mM NaCl (pH 7.4) solution. For SEM analysis, the micro-
particles were dehydrated by a series of ethanol (70%, 80%, 90%
and 100%) and acetone buffer. Then the samples were placed
on an SEM mount with carbon tape, air-dried, coated with
platinum. The SEM images were obtained using PhenomG2 pro
(Phenom-world, the Netherlands) with an accelerating voltage
of 5 kV.
2.4. Determination of protein release
The release of lysozyme from double-layered microspheres in
vitro was quantied by Qubit Protein Assay Kit (Thermo Fisher
Scientic, Australia). The microspheres (2 mg) were incubated
in 5 mL DMEM with vigorous shaking at 37 C. At the desired
time points (0, 1, 2, 3, 4, 6, 8 h) the solution was centrifuged and
1 mL supernatant was collected. The solution was topped up
with addition of 1 mL fresh DMEM. The concentrations of
lysozyme in the supernatant were tested using Qubit Protein
Assay Kit with Qubit 2 Fluorometer (Invitrogen). The release
tests were repeated three times.
The release of SDF-1 and BMP-2 from double-layered
microspheres in vitro was quantied via an enzyme-linked
immunosorbent assay (ELISA) method. The microspheres (2
mg) were incubated in 5 mL DMEM with vigorous shaking at
37 C. At the desired time points (0, 1, 2, 3, 4, 6, 8, 24 h) the
solution was centrifuged and 1 mL supernatant was collected
and stored at20 C. The solution was topped up with addition
of 1 mL fresh DMEM. The concentrations of SDF-1 and BMP-2
were tested using SDF-1 and BMP-2 ELISA kit (Life Tech Aus-
tralia Pty Ltd, Australia) according to the manufacturer's
instructions. Cumulative release ratio was calculated as the
ratio of the cumulative mass of SDF-1 or BMP-2 released at each
time interval to their initial input amount in the microspheres,
respectively. The release tests were repeated three times.
2.5. Cell culture
BMSCs were obtained from 8–10 weeks old C57 mice (mBMSCs)
as described in a previous study.21 All experiment procedures
were performed in accordance with Australian code for the care
and use of animals for scientic purposes (Australian Govern-
ment, National Health and Medical Research Council,This journal is © The Royal Society of Chemistry 2018Australia, 2013) and guidelines to promote the wellbeing of
animals used for scientic purposes (Australian Government,
2008) and were approved by the Animal Ethics Committee of the
Queensland University of Technology (Brisbane, Australia).
Briey, femurs were harvested aer the mouse was sacriced.
The femurs were washed three times by PBS with 1% (v/v)
penicillin/streptomycin (P/S; Gibco®, Life Technologies Pty
Ltd., Australia). Both ends of femurs were removed, and then
the bone marrow was ushed with Dulbecco's modied Eagle's
medium (DMEM; Gibco®, Life Technologies Pty Ltd., Australia)
containing 1% P/S into a 50 mL tube. BMSCs in bone marrow
were collected by centrifugation (1000 rpm, 5 min, 20 C),
washed once with PBS (containing 1% P/S) and then re-
suspended in DMEM containing 10% (v/v) fetal bovine serum
(FBS; In Vitro Technologies, Australia) and 1% P/S. The cellular
suspension was transferred into a culture ask and incubated
with 5% CO2 at 37 C. By day 3, the non-adherent cells were
removed. Adherent cells were then continually incubated in
DMEM with 10% FBS and 1% P/S. Culture medium was
changed every 2–3 days. When reaching 90% conuence, the
cells were passaged by 2 min exposure to 0.25% trypsin (con-
taining 1 mM EDTA, Gibco®, Life Technologies Pty Ltd., Aus-
tralia). Cells within 5 passages were used for in vitro
osteogenesis. Pre-osteoblast cell line MC3T3-E1 was obtained
from American Type Culture Collection (ATCC) and cultured in
DMEM containing 10% (v/v) FBS; and 1% P/S.
2.6. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay
To evaluate the effect of microspheres on the cellular viability of
mBMSCs, MTT assay was performed as previously described.22
Briey, mBMSCs (3000 cells per well, three wells per group) were
stimulated by cultured medium with graded concentrations (0,
50, 100, 250 mg mL1) of microspheres in O, S, B, and S-B
groups, respectively. Aer 24 h, 72 h, 7 d's culture, the culture
medium was replaced by 100 mL of fresh culture medium, and
10 mL MTT solution (0.5 mg mL1, Sigma-Aldrich Pty Ltd.,
Sydney, Australia) was added into each well. Cells were incu-
bated with MTT for 4 h, and then themedium was removed; 200
mL of dimethyl sulfoxide was added into each well to solubilize
the formazan product, which was then read at 495 nm by
a microplate reader (SpectraMax, Plus 384, Molecular Devices,
Inc., United States) to measure the absorbance. All the results
were normalized against the absorbance of blank wells. All the
measurements were repeated three times.
2.7. Chemotaxis assay
A pre-osteoblast cell line MC3T3-E1 was used to test the homing
effect of the microspheres using a trans-well system (Becton
Dickinson Labware, Franklin Lakes, NJ, USA). Three groups
were established: blank control group (C group), S group
(microspheres with 3.3 mg mL1 SDF-1 in the shell layer), S-B
group (microspheres with 3.3 mg mL1 SDF-1 in the shell and
6.6 mg mL1 BMP-2 in the core). The microspheres with 600 mL
complete culture medium were placed in the bottom layer. The
cells (100 mL cell suspension, 36 000 cells per mL) were seededRSC Adv., 2018, 8, 16503–16512 | 16505
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View Article Onlinein the companion culture inserts (8 mm pore size). Aer culture
for 24, 72 and 120 h, cells in the basolateral chamber were
stained with 0.1% crystal violet solution. To quantify the cell
migration, the blue sediments were dissolved with 33% acetic
acid and the absorbance was measured by a microplate reader
(Innite® 200 PRO, Tecan Trading AG, Switzerland) under
595 nm.2.8. In vitro osteogenesis of mBMSCs
To induce the in vitro osteogenesis, mBMSCs were seeded in 6-
well plates at a density of 2  105 cells per well. Aer 24 h post-
seeding, culture medium was replaced by the osteogenic
medium (DMEM containing 10% FBS, 1% P/S, 10 mM b-glyc-
erophosphate, 50 mM ascorbic acid and 100 nM dexametha-
sone; Sigma-Aldrich Pty Ltd., Sydney, Australia), which was
changed every three days. To test the effect of S-B group on the
mBMSCs osteogenesis, S-B microspheres at a dose of 100 mg
mL1 was added into the osteogenic medium; the cells applied
with O, S and B microspheres served as the controls; cells
without microsphere application served as blank controls
(group C). Cells with three days' stimulation were harvested for
RNA extraction and ALP activity assay. Cells stimulated for 14
days were harvested for Alizarin Red S staining.2.9. RNA extraction, cDNA synthesis, and real time
quantitative-PCR (RT-qPCR)
Total RNA of mBMSCs was extracted by the TRIzol reagent
(Ambion®, Life Technologies Pty Ltd., Australia). The cDNA was
then synthesized from 1 mg total RNA by SensiFAST™ cDNA
Synthesis Kit (Bioline Pty Ltd., Australia) following the manu-
facturer's instruction. RT-qPCR was performed through the
QuantStudio™ 7 Flex Real-Time PCR System (Applied Bio-
systems, Australia) with SYBR® Green reagent (Applied Bio-
systems, Australia) according to the manufacturer's
instructions. The RT-qPCR primers used in this study were lis-
ted in Table 1, the designs of which were based on cDNA
sequences from the National Centre for Biotechnology Infor-
mation (NCBI) sequence database. The tests were conducted on
the following target genes: iBSP, COL-1, Osterix, OCN, OPN,
RUNX2, Smad 1/5/8. The house keeping gene GAPDH and b-Table 1 Sequence of primers used for RT-PCR test
Gene Forward sequences
iBSP 50CAG AGG AGG CAA GCG TCA CT30
COL-1 50AGA ACA GCG TGG CCT ACA TG30
Osterix 50AGC GAC CAC TTG AGC AAA CAT30
OCN 50ACC TAG CAG ACA CCA TGA GGA C3
OPN 50CAA TGA AAG CCA TGA CCA CAT GG
RUNX2 50CAGGCAGGTGCTTCAGAACT30
Smad 1 50CGAGCCGGCGCTAAC30
Smad 5 50GGGAGATAAGGATCCGCGCT30
Smad 8 50TGAGTATCACTCTCTTGAGTAAGC30
GAPDH 50TCAGCAATGCCTCCTGCAC30
b-actin 50CTGTCGAGTCGCGTCCACC30
16506 | RSC Adv., 2018, 8, 16503–16512actin were used as control. All reactions were run in triplicate
for three independent experiments. Relative gene expression
was normalized against GAPDH or b-actin and calculated as
previously described.232.10. ALP activity assay
The cells with three days osteogenesis induction were harvested
for ALP activity assay by ALP assay buffer (Abcam, Cambridge,
UK). Protein concentration was measured by the BCA Protein
Assay Kit (Thermo Fisher Scientic, VIC, Australia). The ALP
activity was tested by Alkaline Phosphatase Assay kit (Colori-
metric) (Abcam, Cambridge, UK) following the manufacture's
instruction. All tests were performed in triplicate for three
independent experiments. All the results were expressed as the
calculated ALP activity/protein concentrations.2.11. Alizarin Red S staining
Aer 14 days of osteogenic induction, cells were xed with 4%
PFA for 20 min at room temperature, and then rinsed with
distilled water. Aer that, the cells were stained with 1% Aliz-
arin Red S (Sigma-Aldrich Pty Ltd., Sydney, Australia) solution
(pH: 4.1–4.3) for 20 min at room temperature. Aer washing
three times with distilled water, the samples were air-dried and
observed under microscope (Eclipse TS100, Nikon Australia Pty
Ltd.). The quantication of Alizarin Red staining was performed
by analyzing the percentage of positive area through the Image J
soware. The average number of ve randomly chosen areas of
each sample was calculated. Samples from three independent
replications were analyzed for Alizarin Red S staining intensity.
All measurements were performed in a double-blind manner by
two independent observers.2.12. Statistical analysis
All statistical analysis was carried out using GraphPad Prism 7
(GraphPad Soware, Inc., USA). Statistical analysis was per-
formed using the Student's unpaired t-test for two groups'
comparisons and through one-way variance analysis (ANOVA)
for multiple comparisons (p # 0.05).Reverse sequences
50CTG TCT GGG TGC CAA CAC TG30
50TCC GGT GTG ACT CGT GC30
50GCG GCT GAT TGG CTT CTT CT30
0 50GGG GAC TGA GGC TCC AAG30
30 50CTC ATC TGT GGC ATC AGG ATA CTG30
50ACTCTGGCTTTGGGAAGAGC30
50CCCTGTTTCCACCCAAGGAG30
50GCTTCTTCTTAGTGCAAGTCACAA30
50CACGGGGAAAGAGGATGAGAC30
50TCTGGGTGGCAGTGATGGC30
50ATTCCCACCATCACACCCTGG30
This journal is © The Royal Society of Chemistry 2018
Fig. 1 Schematic illustration of the double-layered microspheres
based growth factors delivery system.
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View Article Online3. Results
3.1. Characterization of the double-layered microspheres
As shown in Fig. 2A, double-layered microspheres were well-
dispersed particles with a uniform spherical shape with the size
of around 380 mm. The double-layered structure could be clearly
observed in Fig. 2B where several small particles (core particles)
were embedded in a big particle (shell particle). To conrm that
two different growth factors were loaded into the different parts of
double-layered microspheres, uorescence dye labelled proteins
(albumin) was used as the drug model and added during the
formation of core particles and shell particles, respectively. From
the uorescence microscopy image (Fig. 2C) red uorescence was
observed from the core particles, which were incorporated inside
large microspheres with green uorescence, conrming the
loading of two proteins in corresponding layers.Fig. 2 Optical microscope images of the double-layered microspher
florescent dyes (C). Inset in (B) showed the SEM image of double-layered
growth factor loaded double-layered microspheres.
This journal is © The Royal Society of Chemistry 20183.2. SDF-1 and BMP-2 release proles from the double-
layered microspheres
The release proles of SDF-1 and BMP-2 from double-layered
microspheres loaded with SDF-1 and BMP-2 were investigated
in vitro. The amount of released growth factors were tested by
corresponding ELISA kits. As shown in Fig. 2D, an initial burst
release of SDF-1 from microspheres was noticed in the rst 6 h,
with about 80% of loaded SDF-1 being set free to the medium.
BMP-2 showed delayed and mild release prole comparing to
SDF-1. 50% of BMP-2 was release in around 4 hours while 50%
of SDF-1 was released in 2 h. The release rate can be further
tuned by changing the coating layers of chitosan. To demon-
strate this, we coated the alginate microspheres with three
layers of chitosan (chitosan–alginate–chitosan–alginate–chito-
san, Fig. 3A), and the z potential changes (minus with alginate
and positive aer chitosan, Fig. 3B) indicated the successful
coating of each layer. Aer that those microspheres went
through another electrospun process to form the double-
layered structure. We used lysozyme as a protein model and
loaded it into the inner microspheres. Microscopy image
(Fig. 3B) showed those microspheres with 3 layers of chitosan
had similar structure with those microspheres with 1 layer of
chitosan and lysozyme release prole (Fig. 3C) showed a slower
release rate. 50% of lysozyme was release at around 6.5 hours in
the case of microspheres with 3 chitosan layers while it took
only 3.5 h for those with 1 chitosan layer.es (A and B) and fluorescence microscope image after loaded with
microsphere. (D) showed the release profiles of SDF-1 and BMP-2 from
RSC Adv., 2018, 8, 16503–16512 | 16507
Fig. 3 Optical microscope image of the inner alginatemicrospheres with three layers of chitosan (A) and the z potential change during the layer-
by-layer coating process (B). (C) showed themicroscope image of double-layeredmicrospheres with three layers of chitosan and (D) showed the
release profiles of lysozyme from double-layered microspheres with one and three layers of chitosan.
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View Article Online3.3. Effect of the double-layered microspheres on cell
viability of mBMSCs
MTT assay was performed to consecutively evaluate the effects
of the double-layered microspheres with multiple cytokines
(SDF-1/BMP-2) on the proliferation of mBMSCs. For O group, noFig. 4 Effects on cell proliferation of growth factor loaded double layer m
S, SDF-1 was loaded in microspheres; (C) B, BMP-2 was loaded in micro
16508 | RSC Adv., 2018, 8, 16503–16512signicant difference regarding mBMSC-proliferation could be
identied among dose groups (0/50/100/250 mg mL1) at each
time point (24 h, 72 h, 7 d), except for 250 mg mL1 on day 7
(Fig. 4A). For the S group (Fig. 4B), S-Ms at doses of 50 and
100 mg mL1 leaded to signicantly increased proliferation of
mBMSCs at 72 h-culture; besides that, no signicant differenceicrospheres ((A) O, no growth factors were loaded in microspheres; (B)
spheres; (D) S-B, SDF-1 and BMP-2 were loaded in microspheres).
This journal is © The Royal Society of Chemistry 2018
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View Article Onlinecould be found among dose groups at each time point. As
shown in Fig. 4C, B-Ms application did not result in any
reduction in the proliferation of mBMSCs; whereas B-Ms at 50/
100/250 mg mL1 leaded to a signicant increase in cellular
growth at 24 h. Also, B-Ms at 50/100 mg mL1 induced cellular
growth at 72 h. For S-B group (Fig. 4D), no signicant difference
could be found within dose groups at each time point.
Compared with the blank-control (0 mgmL1), the O, S, B andS-
B groups at the doses of 50 and 100 mgmL1 did not inhibit the
proliferation mBMSCs. Therefore, 100 mg mL1 was applied in
the following study.
3.4. Double-layered microspheres with SDF-1 induced the
cell migration
To test the effect of SDF-1-loading microspheres on cellular
migration, a chemotaxis assay was performed by the trans-well
system. As shown in Fig. 5, in comparison with the blank
control group (C group, Fig. 5A and B), S-Ms applicationFig. 5 Optical microscope images of MC3T3-E1 cells in chemotaxis
assay after treated with control group (A and B), S group (C and D) and
S-B group (E and F) for 72 h (A, C and E) and 120 h (B, D and F). (G)
shows the optical density (OD) of control group and experimental
groups in chemotaxis assay. *Significantly different from control group
(p < 0.05). Scale bar ¼ 200 mm.
This journal is © The Royal Society of Chemistry 2018attracted more cells migrating from the upper insert to the
lower chamber (S group, Fig. 5C and D). Accordingly, the OD
values of the S group were signicantly higher than those of the
control group at 72 h and 120 h, which further proved that
cellular migration was signicantly induced by S-Ms.
3.5. SDF-1/BMP-2 double-delivery microspheres signicantly
induced the osteogenic differentiation of mBMSCs
As shown in Fig. 6, in comparison with the blank control group
(C group), mBMSCs applied with B and S-B microsphere groups
showed signicantly induced mRNA levels (2 to 4 folds) of the
osteogenic markers: iBSP, COL-1, Osterix, OPN, and RUNX2.
Compared with the C group, cells with O and S microsphere
application did not show signicantly induced expression
regarding iBSP, COL-1, Osterix, and RUNX2; while signicantly
increased mRNA levels regarding these factors were found in B
and S-B groups in comparison with O/S groups. As shown in
Fig. 6D and E, in comparison with the C group, all the groups
showed induced expression of OCN and OPN; whereas the S-B
group did not show any signicant difference on OCN expres-
sion when compared with O and S groups. The mRNA levels of
Smad 1/5/8 were signicantly induced in mBMSCs within S-B
group. Moreover, the cells in S-B group signicantly up-
regulated ALP activity, as compared with group C, O and S
(Fig. 7).
3.6. SDF-1/BMP-2 double-delivery microspheres signicantly
induced mineralization of mBMSCs
To test the effect of the S-B group on mineralization, Alizarin
Red S staining was performed to identify the mineralization
nodules. As shown in Fig. 8D and E, both B and S-Bmicrosphere
applications showed enhanced mineralization of mBMSCs, as
compared with the controls (group C, O and S) (Fig. 8A–C). The
positive areas of Alizarin Red S were calculated; as shown in
Fig. 8F. Positive areas in both B and S-B groups signicantly
increased, as compared with those in the blank control (C
group) and the O/S groups (Fig. 8F). No signicant difference
could be found within the control groups (group C, O and S) or
between the B and the S-B groups.
4. Discussion
Microsphere based drug delivery systems have been one of the
most popular research topics in recent decades. This is due to
the potential benets of achieving the long-time effects of the
drug while minimizing the side-effects, therefore making great
improvements to the current drug-based clinical therapies.24–26
Solid microspheres usually designed for single drug loading
and release, have been unable to meet the requirements of
combination therapies in bone regeneration, in which multiple
drugs of diverse therapeutic purposes/effects are used to
improve the outcomes of treatments.27–30 Core-shell micro-
spheres offer several advantages over solid spheres such as the
ability to load multiple drugs and precisely control the release
order, timing and dose.31 Another big challenge for drug
delivery systems is to maintain the bioactivity of loaded drugsRSC Adv., 2018, 8, 16503–16512 | 16509
Fig. 6 Real-time PCR analysis of osteogenic genes (iBSP, COL-1, Osterix, OCN, OPN, RUNX2) and Smad signaling genes (Smad 1, 5, 8) under
osteogenic induction for 7 days (n ¼ 3 per group; *p < 0.05).
Fig. 7 Quantitative ALP activity of BMSCs cultured in different treat-
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View Article Onlineespecially for those protein drugs.32–35 In this study, the novel
alginate core–shell microspheres were prepared by electrospray
to achieve a differential delivery of growth factors and also
maintain the biological functions. As shown in Fig. 1, stromal
cell derived factor-1 (SDF-1), a member of the CXC chemokine
family, was loaded into the shell part to trigger the migration of
MSCs to injury sites during the acute phase of bone repair and
encourage participation in regeneration. Bone morphogenetic
protein-2 (BMP-2), the key osteoinductive growth factor, which
has been approved by the US FDA for clinical use to induce bone
formation via the enhancement of osteogenic differentiation,
was loaded into the core part. With our rational design, the
effects of the sequential and sustained release of SDF-1 and
BMP-2 on the migratory and osteogenic capacity of MSCs and
bone regeneration were assessed in vitro.
From the characterization data (Fig. 2B), it can be observed
that the double-layered microsphere consisted of several small
particles (inner-layer core particles) and one big shell (outer-
layer particle). To test the multiple drug delivery capacity of
this microsphere, red/green uorescence dye labelled albumins
were loaded into the inner core and outer shell. As shown in16510 | RSC Adv., 2018, 8, 16503–16512Fig. 2C, the red core was embedded into the large green shell,
indicating that this double-layer microsphere was successful
fabricated and suitable for double growth factor (SDF-1 and
BMP-2) loading.
To test the release properties of the double-layer micro-
sphere, ELISA assay was performed. As shown in Fig. 2D, SDF-1
and BMP-2 were differentially released from the microspheres;ment groups at day 7 (n ¼ 3 in each group; *p < 0.05).
This journal is © The Royal Society of Chemistry 2018
Fig. 8 Alizarin Red staining of BMSCs (A–E) with different treatment group sunder osteogenic induction for 14 days. F showed the quantification
of Alizarin Red staining.
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View Article OnlineSDF-1 release was faster than that of BMP-2. Hence, it can be
proposed that the SDF-1/BMP-2 double-delivery microspheres
could release SDF-1 rstly to induce MSCs recruitment, and
then release BMP-2 to facilitate their osteogenic differentiation.
The biocompatibility of this microsphere was then tested by
MTT assay, and from the results in Fig. 4, it could be observed
that the double-layer microsphere merely affected the viability
of mBMSCs aer 7 days' stimulation, indicating the good
biocompatibility of this microsphere.
The cell chemotaxis properties of SDF-1 and SDF-1/BMP-2
loading microspheres were then veried. As shown in Fig. 5,
microspheres containing SDF-1 and SDF-1/BMP-2 showed
signicantly induced cell migration aer 72 h, indicating that
the released SDF-1 could effectively attract more MSCs to
migrate towards the injury sites in vivo.
The effect of the SDF-1/BMP-2 double-delivery microspheres
on osteogenesis was then systematically examined in vitro. The
current study found that SDF-1/BMP-2 double-delivery micro-
spheres showed superior osteoinductive capacity, as the S-B-Ms
application induced the osteogenic differentiation of mBMSCs.
As shown in Fig. 6, in comparison with the controls that carried
no microspheres, void microspheres and microspheres with
SDF-1, mBMSCs with S-B-Ms showed signicantly enhanced
mRNA levels in the number of osteogenic markers. Similarly,
mBMSCs with B-Ms also showed increased expression of oste-
ogenic markers, indicating that the BMP-2 released by micro-
spheres could effectively induce the osteogenic differentiation.
The BMP-2 mediated osteogenesis has been shown to occur
because of the Smad signaling,36–38 therefore, the mRNA levels
of Smad 1/5/8 were also examined; and the cells with S-B-Ms
showed signicantly induced expression of Smad 1/5/8
(Fig. 6G–I). This further proved that the effect of S-B-Ms-This journal is © The Royal Society of Chemistry 2018mediated osteoinduction was due to the released BMP-2.
Moreover, cells applied with S-B-Ms showed the highest
activity of ALP (Fig. 6) the key factor in osteogenic differentia-
tion.39,40 Therefore, the osteoinductive properties of the SDF-1/
BMP-2 double-delivery microspheres were conrmed. It was
observed that there were differences between the B and S-B
groups on the expression of osteogenic markers, such as iBSP,
Col-1, OCN, and Smad 1/5. This might be due to the different
BMP-2 release proles between the B-Ms and S-B-Ms. The effect
of the SDF-1/BMP-2 double-delivery microspheres on minerali-
zation was then tested. It was observed that aer 14 days
osteoinduction, cells applied with S-B-Ms and B-Ms achieved
muchmore mineralization than the blank/O-/S-controls (Fig. 7).
All these results demonstrated the osteoinductive ability of SDF-
1/BMP-2 double-delivery microspheres.
When all results in this study are considered together,
a novel double-drug delivery system has been successfully
prepared, which showed good capability in loading and release
of multiple drugs. The double-layer structure not only guaran-
tees the loading of different drugs, but also makes the system
able to release the drugs in a differential manner. The SDF-1/
BMP-2 double-delivery microspheres showed superior perfor-
mance in inducing the migration and osteogenic differentiation
of MSCs in vitro, which was due to the differentially released
SDF-1 and BMP-2. Therefore, the current study provides
a promising novel approach for drug delivery and bone tissue
regeneration. Further in vivo studies should be performed to
further this effect in vivo.
5. Conclusion
Double layered microspheres with dual growth factors delivery
ability were successfully fabricated via two steps electrosprayRSC Adv., 2018, 8, 16503–16512 | 16511
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View Article Onlinemethod. Cell homing test showed an obvious chemotaxis effect
on preosteoblasts of our double layered microspheres. For
osteoinductive ability tests, S-B MC showed much higher ALP
activity and more mineralized modules than control groups
aer 2 weeks' culture. The RT-PCR tests of key transcription
factors (Runx2, OCN, Osterix) that regulate bone development
and important bone forming signals (Smad 1, 5, 8) showed
much higher gene expression in dual growth factors group.
These results suggest the potential of our microspheres as drug
delivery system for biomedical applications.Conflicts of interest
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